Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
31 hedge funds and large institutions have $56.7M invested in Sinovac Biotech, Ltd in 2017 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 9 closing their positions.
193% more call options, than puts
Call options by funds: $776K | Put options by funds: $265K
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less funds holding
Funds holding: 35 → 31 (-4)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
56% less capital invested
Capital invested by funds: $127M → $56.7M (-$70.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$3.87M |
| 2 |
O
OrbiMed
New York
|
+$1.29M |
| 3 |
SIM
Spark Investment Management
New York
|
+$361K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$308K |
| 5 |
Barclays
London,
United Kingdom
|
+$183K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$4.68M |
| 2 |
GP
GLG Partners
London,
United Kingdom
|
-$3.65M |
| 3 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$699K |
| 4 |
Millennium Management
New York
|
-$409K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$256K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
APA
26
American Portfolios Advisors
Holbrook,
New York
| $9.46K | +$8.98K | +1,200 | New |
|
27
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| $4K | – | – | – |
|
28
Simplex Trading
Chicago,
Illinois
| $2K | -$11.2K | -1,497 | -85% |
|
|
LTFS
29
Ladenburg Thalmann Financial Services
Miami,
Florida
| $2K | – | – | – |
|
|
GWM
30
Geneos Wealth Management
Englewood,
Colorado
| $1K | – | – | – |
|
|
WAM
31
Wolverine Asset Management
Chicago,
Illinois
| – | -$699K | -99,212 | Closed |
|
|
32
Millennium Management
New York
| – | -$409K | -58,083 | Closed |
|
33
Walleye Trading
New York
| – | -$346 | -49,065 | Closed |
|
|
34
Citadel Advisors
Miami,
Florida
| – | -$256K | -34,193 | Closed |
|
35
Two Sigma Advisers
New York
| – | -$214K | -30,400 | Closed |
|
|
VAM
36
Verity Asset Management
Durham,
North Carolina
| – | -$98K | -13,542 | Closed |
|
|
VF
37
Virtu Financial
New York
| – | -$71K | -10,119 | Closed |
|
38
UBS Group
Zurich,
Switzerland
| – | -$14K | -2,048 | Closed |
|
39
SEI Investments
Oaks,
Pennsylvania
| – | +$127 | +17 | New |
|
SVA Hedge Fund Activity: Q4 2017 in Review
31 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q4 2017, worth a combined $56.7M — down 56% from $127M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of SVA and 6 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 9 added.
The largest buyer was Renaissance Technologies, adding an estimated $3.87M. The largest seller was Morgan Stanley, cutting an estimated $4.68M.
- 31 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q4 2017, down from 35 in Q3 2017.
- Funds reported $56.7M of Sinovac Biotech, Ltd stock for Q4 2017, down 56% quarter-over-quarter.
- 6 funds opened new Sinovac Biotech, Ltd positions in Q4 2017 and 9 closed out, a net change of -3 holders.
- The largest Sinovac Biotech, Ltd buyer in Q4 2017 was Renaissance Technologies, an estimated $3.87M added.
- The largest Sinovac Biotech, Ltd seller in Q4 2017 was Morgan Stanley, an estimated $4.68M sold.
Based on aggregated 13F filings for Q4 2017.